Justin Hean, Carol Crowther, Abdullah Ely, Rafique Ul Islam, Samantha Barichievy, Kristie Bloom, Marc S Weinberg, Willem Al van Otterlo, Charles B de Koning, Felix Salazar, Patricia Marion, Eric B Roesch, Marc Lemaitre, Piet Herdewijn, Patrick Arbuthnot
Chronic infection with the hepatitis B virus (HBV) occurs in approximately 6% of the world's population and carriers of the virus are at risk for complicating hepatocellular carcinoma. Current treatment options have limited efficacy and chronic HBV infection is likely to remain a significant global medical problem for many years to come. Silencing HBV gene expression by harnessing RNA interference (RNAi) presents an attractive option for development of novel and effective anti HBV agents. However, despite significant and rapid progress, further refinement of existing technologies is necessary before clinical application of RNAi-based HBV therapies is realized...
July 2010: Artificial DNA, PNA & XNA